39 related articles for article (PubMed ID: 35462489)
1. [Observation of PD-1
He J; Yao YQ; Xia RX; Qiu TJ; Long L; Wang Y; Jiang Y
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):316-322. PubMed ID: 35462489
[No Abstract] [Full Text] [Related]
2. Bushen Formula promotes the decrease of HBsAg levels in patients with CHB by regulating Tfh cells and B-cell subsets.
Ji L; Wei J; Zhang R; Zhang X; Gao Y; Fang M; Yu Z; Cao L; Gao Y; Li M
J Ethnopharmacol; 2024 Jun; 328():118072. PubMed ID: 38508431
[TBL] [Abstract][Full Text] [Related]
3. [Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].
Pan JL; Luo H; Zhang XX; Han YF; Chen HY; Zeng Z; Xu XY
Zhonghua Gan Zang Bing Za Zhi; 2024 Jan; 32(1):16-21. PubMed ID: 38320786
[No Abstract] [Full Text] [Related]
4. [Study of the predictive role of serum HBV RNA on HBeAg serological conversion in children with chronic hepatitis B].
Xu JJ; Shi C; Hong XQ; Chu F; Bai QK; Wang J; Shi YM; Guo ZX; Zhang XR; Wang FC; Zhang M; Chang XT; Zhang XC; Zhong YW
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1182-1186. PubMed ID: 38238952
[No Abstract] [Full Text] [Related]
5. [Inhibitory effect of small-molecule compound AM679 targeting elongation-factor binding protein 2 on hepatitis B virus in vitro].
Fang HJ; Cai JY; Hou XX; Song JL; Peng LY; Zhu CL
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):318-324. PubMed ID: 38733186
[No Abstract] [Full Text] [Related]
6. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract][Full Text] [Related]
7. A mutual regulatory loop between transcription factor Yin Yang 1 and hepatitis B virus replication influences chronic hepatitis B.
Zhou J; Hua Y; Liu Y; Wu T; Xu H; Wang Z; Wang X; Niu J
Antiviral Res; 2024 Jun; 226():105889. PubMed ID: 38631661
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection.
Mukherjee R; Reddy PB; Arava J; Rao P; Mitnala S; Gupta R; Reddy D
Hepat Med; 2010; 2():157-62. PubMed ID: 24367213
[TBL] [Abstract][Full Text] [Related]
9. IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.
Chua C; Salimzadeh L; Ma AT; Adeyi OA; Seo H; Boukhaled GM; Mehrotra A; Patel A; Ferrando-Martinez S; Robbins SH; La D; Wong D; Janssen HLA; Brooks DG; Feld JJ; Gehring AJ
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38055623
[TBL] [Abstract][Full Text] [Related]
10. CXCR5
Liu Z; Zhao Z; Xie H; Lu N; Liu J; Jiao Q
Front Immunol; 2024; 15():1295309. PubMed ID: 38426098
[TBL] [Abstract][Full Text] [Related]
11. Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection.
Jiang B; Wang L; Liu H; Wang L; Su R; Xu L; Wei G; Li J; Lu F; Chen X
J Med Virol; 2024 Apr; 96(4):e29569. PubMed ID: 38549467
[TBL] [Abstract][Full Text] [Related]
12. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.
Kadelka S; Dahari H; Ciupe SM
Sci Rep; 2021 Jan; 11(1):200. PubMed ID: 33420293
[TBL] [Abstract][Full Text] [Related]
13. Exhaustion of CD8+ T Cells in HBV Infection: Searching for Serological Markers.
Peng L; Feng J; Liu X
Ann Clin Lab Sci; 2023 Nov; 53(6):938-945. PubMed ID: 38182157
[TBL] [Abstract][Full Text] [Related]
14. Role of CXCR5
Zhou J; He X; Ou Y; Peng S; Li D; Zhou Q; Fu J; Long Y; Tan Y
J Viral Hepat; 2023 Aug; 30(8):638-645. PubMed ID: 37129474
[TBL] [Abstract][Full Text] [Related]
15. CD32 Expression by CD4
Yao CY; Hu ZS; Yuan RL; Jin J; Chen ZX
Viral Immunol; 2023 Jun; 36(5):351-359. PubMed ID: 37289774
[TBL] [Abstract][Full Text] [Related]
16. PD-1
Asashima H; Mohanty S; Comi M; Ruff WE; Hoehn KB; Wong P; Klein J; Lucas C; Cohen I; Coffey S; Lele N; Greta L; Raddassi K; Chaudhary O; Unterman A; Emu B; Kleinstein SH; Montgomery RR; Iwasaki A; Dela Cruz CS; Kaminski N; Shaw AC; Hafler DA; Sumida TS
Cell Rep; 2023 Jan; 42(1):111895. PubMed ID: 36596303
[TBL] [Abstract][Full Text] [Related]
17. Potential role of Vitamin D in immune response in patients with viral hepatitis.
Gerhards C; Teufel A; Gerigk M; French M; Antoni C; Ebert M; Neumaier M; Evliyaoglu O
Nutrition; 2024 Mar; 124():112447. PubMed ID: 38669827
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic effect of IL-21 combined with IFN-γ inducing CD4
Zhao C; Wu X; Chen J; Qian G
J Adv Res; 2022 Feb; 36():89-99. PubMed ID: 35127167
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus e antigen induces atypical metabolism and differentially regulates programmed cell deaths of macrophages.
Li Y; Wu C; Lee J; Ning Q; Lim J; Eoh H; Wang S; Hurrell BP; Akbari O; Ou JJ
PLoS Pathog; 2024 Mar; 20(3):e1012079. PubMed ID: 38466743
[TBL] [Abstract][Full Text] [Related]
20. Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study.
Crane JC; Gordon MJ; Basen-Engquist K; Ferrajoli A; Markofski MM; Lee CY; Fares S; Simpson RJ; LaVoy EC
Eur J Haematol; 2023 Jun; 110(6):732-742. PubMed ID: 36946440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
